Affinivax Garners $4,000,000 New Round

  • Feed Type
  • Date
  • Company Name
  • Mailing Address
    Undisclosed Cambridge, MA 02139 USA
  • Company Description
    Affinivax is a biotechnology company developing a novel conjugation technology with the goal of designing vaccines that provide broad protection against challenging diseases afflicting children and adults in both the developing and developed worlds.
  • Website
  • Transaction Type
    Venture Equity
  • Transaction Amount
  • Transaction Round
  • Proceeds Purposes
    The company intends to use the funds to develop its Multiple Antigen Presenting System (MAPS) technology platform and enable the development of novel vaccines to protect children and adults in both the developed and developing worlds, with an initial focus on its lead drug program for Streptococcus pneumoniae (pneumococcus).
  • M&A Terms
  • Venture Investor

Trending on Xconomy